Innate Immune Receptors for Toxoplasma gondii

弓形虫先天免疫受体

基本信息

项目摘要

DESCRIPTION (provided by applicant): Toll-Like Receptors (TLRs) are a primary mean whereby the innate immune system recognizes and rapidly responds to microbes. Studies employing the mouse models of toxoplasmosis indicate that the Myeloid Differentiation Factor 88 (MyD88), an adaptor-signaling molecule for the TLRs, is critical for initiation of early inflammatory responses and host resistance to infection with T. gondii. At least three TLRs (i.e. TLR2, TLR4 and TLR11) are involved in activation of the innate immune system and host resistance during T. gondii infection in mice. Human TLR 11 has a stop codon making this protein apparently nonfunctional. The main goal of our project is to characterize mechanisms whereby the human innate immune system responds to infection with T. gondii. Specifically, we will test the hypotheses that in humans, TLRs are key cognate receptors involved in the innate immune response to T. gondii tachyzoites, influence development of cell- mediated immunity, and that polymorphisms in TLRs related molecules affects human susceptibility to T. gondii infection. We will characterize the ability of tachyzoites, including their glycosylphospatidylinositol (GPI) and glycosylinositolphospholipids (GIPLs) or other glycolipids, as determined by a lipidomic approach, to bind and signal human cells via TLRs. Our focus will be on TLR2 and TLR4. Using single nucleotide polymorphisms (SNPs) we will look for allelic variation in the genes encoding the relevant TLRs as well as proteins in the signaling pathways that are critical for the functions triggered by TLRs. To determine whether there are associations with disease due to T. gondii in humans, we will characterize TLRs in patients with congenital toxoplasmosis and their parents, and in patients with ocular toxoplasmosis that remains stable or that recurs frequently. We will also evaluate whether allelic variations in TLR genes influence innate and acquired immunologic responses elicited by T. gondii in asymptomatic as well as patients with congenital disease, or acquired ocular toxoplasmosis. T. gondii causes eye disease and neurologic damage in congenitally infected individuals; in addition it affects immunocompromised persons and eye disease in a proportion of those who acquire T. gondii postnatally. Identification of the mechanisms of innate immunity involved in parasite recognition and that influence immune response during T. gondii infection will provide important information about new-strategies that may be applicable in vaccine development and therapy of human toxoplasmosis that maybe used to control parasite transmission, lessen the pathologies mentioned above and to improve the prognosis of the disease.
描述(由申请人提供):toll样受体(TLRs)是先天免疫系统识别和快速响应微生物的主要手段。采用小鼠弓形虫模型的研究表明,髓样分化因子88 (MyD88)是tlr的一种适配器信号分子,对于早期炎症反应的启动和宿主对弓形虫感染的抵抗至关重要。至少有三种tlr(即TLR2、TLR4和TLR11)参与了小鼠弓形虫感染过程中先天免疫系统的激活和宿主的抗性。人类tlr11有一个终止密码子,使该蛋白明显不起作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICARDO TOSTES GAZZINELLI其他文献

RICARDO TOSTES GAZZINELLI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICARDO TOSTES GAZZINELLI', 18)}}的其他基金

Granzyme and Granulysin Mediated Death of Trypanosoma cruzi
颗粒酶和颗粒溶素介导的克氏锥虫死亡
  • 批准号:
    9229525
  • 财政年份:
    2016
  • 资助金额:
    $ 59.18万
  • 项目类别:
Granzyme and Granulysin Mediated Death of Trypanosoma cruzi
颗粒酶和颗粒溶素介导的克氏锥虫死亡
  • 批准号:
    9104713
  • 财政年份:
    2016
  • 资助金额:
    $ 59.18万
  • 项目类别:
Monocyte-derived dendritic cells in malaria
疟疾中的单核细胞衍生树突状细胞
  • 批准号:
    9282641
  • 财政年份:
    2016
  • 资助金额:
    $ 59.18万
  • 项目类别:
Amazonian Center of Excellence in Malaria Research
亚马逊疟疾研究卓越中心
  • 批准号:
    10441617
  • 财政年份:
    2010
  • 资助金额:
    $ 59.18万
  • 项目类别:
Amazonian Center of Excellence in Malaria Research
亚马逊疟疾研究卓越中心
  • 批准号:
    10598090
  • 财政年份:
    2010
  • 资助金额:
    $ 59.18万
  • 项目类别:
2009 Molecular Approaches for Emergent Re-emergent Tropical Diseases Gordon Resea
2009 年新兴热带病的分子方法 Gordon Resea
  • 批准号:
    7611715
  • 财政年份:
    2009
  • 资助金额:
    $ 59.18万
  • 项目类别:
Role of Polymorphonuclear Phagocytes in Malaria Sepsis
多形核吞噬细胞在疟疾败血症中的作用
  • 批准号:
    7753475
  • 财政年份:
    2009
  • 资助金额:
    $ 59.18万
  • 项目类别:
Role of Polymorphonuclear Phagocytes in Malaria Sepsis
多形核吞噬细胞在疟疾败血症中的作用
  • 批准号:
    7894695
  • 财政年份:
    2009
  • 资助金额:
    $ 59.18万
  • 项目类别:
Innate Immune Receptors for Toxoplasma gondii
弓形虫先天免疫受体
  • 批准号:
    7152613
  • 财政年份:
    2006
  • 资助金额:
    $ 59.18万
  • 项目类别:
Innate Immune Receptors for Toxoplasma gondii
弓形虫先天免疫受体
  • 批准号:
    7487930
  • 财政年份:
    2006
  • 资助金额:
    $ 59.18万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 59.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 59.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 59.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了